There has been much speculation on the subject of the utility of antibody status (acetylcholine receptor antibody positive (AChR+ve) vs MuSK antibody-positive) in prognostication and arranging therapy
There has been much speculation on the subject of the utility of antibody status (acetylcholine receptor antibody positive (AChR+ve) vs MuSK antibody-positive) in prognostication and arranging therapy.[3] AIM OF THE STUDY This is a single-center, ambispective, comparative study comparing demographic and clinical characteristics, treatment response, and outcome of MuSK+ve MG with AChR+ve MG and patients with double-seronegative myasthenia (DN-MG). Rabbit Polyclonal to GRAK MATERIALS AND METHODS A retrospective chart review of MuSK+ve MG presenting to our institute from January 2010 to January 2016 was performed. Seropositivity for antibodies should not be used in isolation to guide the management or forecast the prognosis. Undue bad prognostication may impact the morale of individual. Clinical features and response to therapy in addition to antibody status must be regarded as before planning therapy. in…